- Enovis Corporation recently reported its fourth-quarter and full-year 2025 results, including sales of US$575.76 million for the quarter and US$2.25 billion for the year, alongside a goodwill impairment charge of US$501.31 million that kept the company in a loss-making position.
- At the same time, Enovis issued 2026 guidance calling for US$2.31 billion to US$2.37 billion in revenue and 4–6% organic growth, highlighting how ongoing product innovation and margin efforts are being weighed against repeated, very large goodwill write-downs.
- Next, we’ll examine how this mix of mid-single-digit organic growth guidance and very large goodwill impairment reshapes Enovis’s investment narrative.
The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.
Enovis Investment Narrative Recap
To own Enovis, you need to believe that its orthopedic innovation pipeline and improving operations can eventually translate mid single digit organic growth into sustainable profitability, despite ongoing losses. The latest results and another US$501.31 million goodwill impairment keep the headline numbers firmly in the red, so the key short term catalyst remains execution on product launches and margins, while the biggest risk is that repeated, very large write downs signal deeper issues with past acquisitions and capital allocation.
The most relevant recent announcement is Enovis’s 2026 guidance for US$2.31 billion to US$2.37 billion in revenue and 4–6% organic growth. This outlook ties directly into the current catalyst: proving that innovation such as ARVIS, OrthoDrive Impactor and new reconstructive offerings can support steady organic growth even as the company absorbs the earnings impact of further goodwill impairments and works to improve cash generation and balance sheet flexibility.
Yet beneath the innovation story, investors should be aware that repeated goodwill impairments and persistent net losses could signal...
Read the full narrative on Enovis (it's free!)
Enovis’ narrative projects $2.6 billion revenue and $329.3 million earnings by 2028.
Uncover how Enovis' forecasts yield a $45.09 fair value, a 78% upside to its current price.
Exploring Other Perspectives
Before this news, the most optimistic analysts were assuming revenue could reach about US$2.7 billion with a sharp earnings swing into profit, which contrasts sharply with concerns around execution risk on key innovation programs such as Arvis Ultra and Nebula Stem and highlights how differently you might view the same guidance range.
Explore 2 other fair value estimates on Enovis - why the stock might be worth over 2x more than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Enovis research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Enovis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Enovis' overall financial health at a glance.
Contemplating Other Strategies?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
- The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com